Christoph Röllig

16.5k total citations · 1 hit paper
143 papers, 3.4k citations indexed

About

Christoph Röllig is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Christoph Röllig has authored 143 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Hematology, 43 papers in Molecular Biology and 37 papers in Genetics. Recurrent topics in Christoph Röllig's work include Acute Myeloid Leukemia Research (87 papers), Multiple Myeloma Research and Treatments (34 papers) and Hematopoietic Stem Cell Transplantation (22 papers). Christoph Röllig is often cited by papers focused on Acute Myeloid Leukemia Research (87 papers), Multiple Myeloma Research and Treatments (34 papers) and Hematopoietic Stem Cell Transplantation (22 papers). Christoph Röllig collaborates with scholars based in Germany, United States and Spain. Christoph Röllig's co-authors include Martin Bornhäuser, Gerhard Ehninger, Stefan Knop, Christian Thiede, Michael Krämer, Uwe Platzbecker, Johannes Schetelig, Markus Schaich, Brigitte Mohr and Martin Wermke and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christoph Röllig

136 papers receiving 3.4k citations

Hit Papers

Multiple myeloma 2014 2026 2018 2022 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multiple myeloma
    2014 461 citations Christoph Röllig, Stefan Knop et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christoph Röllig Germany 30 2.4k 1.2k 943 595 570 143 3.4k
Martin Wermke Germany 25 2.2k 0.9× 1.2k 1.0× 1.2k 1.2× 885 1.5× 517 0.9× 152 3.7k
Tibor Kovacsovics United States 29 2.3k 1.0× 1.4k 1.1× 880 0.9× 639 1.1× 433 0.8× 123 3.7k
Thomas Pabst Switzerland 30 2.5k 1.0× 1.6k 1.3× 1.2k 1.3× 713 1.2× 376 0.7× 180 4.3k
Luca Maurillo Italy 30 2.0k 0.8× 1.1k 0.9× 499 0.5× 1.1k 1.9× 535 0.9× 134 3.3k
David A. Sallman United States 31 2.6k 1.1× 1.6k 1.3× 992 1.1× 1.0k 1.7× 869 1.5× 293 3.8k
Sergej Konoplev United States 35 2.2k 0.9× 1.4k 1.1× 1.4k 1.5× 1.2k 2.1× 1.1k 1.9× 154 4.6k
Meral Beksaç Türkiye 23 2.3k 0.9× 1.3k 1.0× 1.3k 1.4× 452 0.8× 379 0.7× 118 3.0k
Lucía López‐Corral Spain 28 1.6k 0.7× 934 0.8× 699 0.7× 347 0.6× 289 0.5× 91 2.2k
Aziz Nazha United States 27 1.6k 0.7× 777 0.6× 288 0.3× 836 1.4× 167 0.3× 170 2.5k
Brigitte Mohr Germany 30 3.5k 1.5× 1.3k 1.1× 558 0.6× 1.3k 2.1× 449 0.8× 79 4.2k

Countries citing papers authored by Christoph Röllig

Since Specialization
Citations

This map shows the geographic impact of Christoph Röllig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Röllig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Röllig more than expected).

Fields of papers citing papers by Christoph Röllig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph Röllig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Röllig. The network helps show where Christoph Röllig may publish in the future.

Co-authorship network of co-authors of Christoph Röllig

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Röllig. A scholar is included among the top collaborators of Christoph Röllig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Röllig. Christoph Röllig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eckardt, Jan‐Niklas, Susann Winter, Katja Sockel, et al.. (2025). Image-based explainable artificial intelligence accurately identifies myelodysplastic neoplasms beyond conventional signs of dysplasia. npj Precision Oncology. 10(1). 26–26.
2.
Stasik, Sebastian, Jan‐Niklas Eckardt, Christoph Röllig, et al.. (2025). The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML. British Journal of Haematology. 206(5). 1373–1379.
3.
Röllig, Christoph, Christoph Schliemann, Leo Ruhnke, et al.. (2024). Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: Results from the SAL‐MODULE phase I study. British Journal of Haematology. 204(6). 2254–2258. 3 indexed citations
4.
Schlenk, Richard F., Jan Moritz Middeke, Stefan W. Krause, et al.. (2024). Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML. Blood Advances. 9(2). 375–385. 1 indexed citations
5.
Ravandi‐Kashani, Farhad, Aaron D. Goldberg, Elie Traer, et al.. (2023). PHASE 1 STUDY OF PRT1419 (MCL1 INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID OR B‐CELL MALIGNANCIES. Hematological Oncology. 41(S2). 834–835. 2 indexed citations
6.
Jonas, Brian A., Jing‐Zhou Hou, Gail J. Roboz, et al.. (2023). A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Hematological Oncology. 41(4). 743–752. 12 indexed citations
7.
Sockel, Katja, Friedrich Stölzel, Christoph Röllig, et al.. (2022). Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse. SHILAP Revista de lepidopterología. 3 indexed citations
8.
Perl, Alexander E., Naoko Hosono, Pau Montesinos, et al.. (2022). Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer Journal. 12(5). 84–84. 27 indexed citations
9.
Krämer, Michael, Christian Thiede, Stefan W. Krause, et al.. (2022). Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. Leukemia. 36(9). 2208–2217. 12 indexed citations
10.
Eckardt, Jan‐Niklas, Michael Krämer, Katja Sockel, et al.. (2022). Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears. BMC Cancer. 22(1). 201–201. 41 indexed citations
11.
Vučinić, Vladan, Leo Ruhnke, Katja Sockel, et al.. (2021). The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia. Blood Advances. 5(24). 5584–5587. 10 indexed citations
12.
Eckardt, Jan‐Niklas, Jan Moritz Middeke, Michael Krämer, et al.. (2021). Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears. Leukemia. 36(1). 111–118. 60 indexed citations
13.
Röllig, Christoph, Christoph Schliemann, Jan‐Henrik Mikesch, et al.. (2021). Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study. Blood. 138(Supplement 1). 2324–2324. 6 indexed citations
14.
Heuschkel, Sandra, Raphael Teipel, Simone von Bonin, et al.. (2021). Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury. Cancer Chemotherapy and Pharmacology. 89(1). 41–48. 6 indexed citations
15.
Stölzel, Friedrich, Steffen Löck, Stefani Parmentier, et al.. (2019). The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the prospective PETAML trial. Haematologica. 105(6). 1552–1558. 34 indexed citations
16.
Strifler, Susanne, Inken Hilgendorf, Martina Kleber, et al.. (2015). The Contribution of a Third Autologous Stem Cell Transplant in the Era of Novel Agents: Favourable Overall Survival and Improvement of Exhausted Bone Marrow Function. Clinical Lymphoma Myeloma & Leukemia. 15. e287–e288. 1 indexed citations
17.
Ehninger, Armin, Michael Krämer, Christoph Röllig, et al.. (2014). Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer Journal. 4(6). e218–e218. 260 indexed citations
18.
Röllig, Christoph, Stefan Knop, & Martin Bornhäuser. (2014). Multiple myeloma. The Lancet. 385(9983). 2197–2208. 461 indexed citations breakdown →
19.
Bornhäuser, Martin, Ulrich Klenk, Christoph Röllig, et al.. (2004). Mixed response after allogeneic haemopoieticcell transplantation for metastatic renal-cell carcinoma. The Lancet Oncology. 5(3). 191–192. 2 indexed citations
20.
Babatz, Jana, Christoph Röllig, Uta Oelschlägel, et al.. (2003). Large-Scale Immunomagnetic Selection of CD14 + Monocytes to Generate Dendritic Cells for Cancer Immunotherapy: A Phase I Study. Journal of Hematotherapy & Stem Cell Research. 12(5). 515–523. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Wermke Breakdown of academic impact, for papers by Tibor Kovacsovics Breakdown of academic impact, for papers by Thomas Pabst Breakdown of academic impact, for papers by Luca Maurillo Breakdown of academic impact, for papers by David A. Sallman Breakdown of academic impact, for papers by Sergej Konoplev Breakdown of academic impact, for papers by Meral Beksaç Breakdown of academic impact, for papers by Lucía López‐Corral Breakdown of academic impact, for papers by Aziz Nazha Breakdown of academic impact, for papers by Brigitte Mohr
Rankless by CCL
2026